NCT04235959View on ClinicalTrials.gov

A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 21, 2020

Primary Completion Date

August 17, 2021

Study Completion Date

August 17, 2021

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Tirzepatide

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (2)

100034

Peking University First Hospital, Beijing

610041

West China Hospital Sichuan University, Chengdu

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04235959 - A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter